AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 182 min read$LGND

Sabba Stephen L sold $545K of LGND

Sabba Stephen L sold 2,145 shares of LIGAND PHARMACEUTICALS INC (LGND) at $254.00 ($0.54M total) on 2026-06-16.

Original reporting
SEC EDGAR · Sabba Stephen L
Published Jun 18, 2026, 12:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 1:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LGND
Neutral
high confidence
Mentioned
$LGND
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LGNDNeutralLow
01

Why it matters

The disclosed fact is an open-market sale by a director; it may modestly influence sentiment but does not provide new company performance, guidance, or regulatory information.

02

Market read

Traders may note the insider sale for sentiment/positioning, but there is no fundamental catalyst in the text.

03

What to watch

The filing does not state a 10b5-1 plan; however, the article provides no context on motivations, option exercises, or prior trading patterns.

Relevance 5/10Novelty 3/10Timing: New Form 4 filed 2026-06-18 (sale dated 2026-06-16).

Background

The article is a SEC Form 4 insider transaction disclosure for Ligand Pharmaceuticals (LGND).

Company-level read

Ticker impact

$LGNDNeutralHigh confidence
Context

Director Sabba Stephen L filed a Form 4 open-market sale of 2,145 shares at $254 on 2026-06-16, totaling $544,830.

Expected impact

Low near-term impact; any effect is likely sentiment-only and short-lived.

Evidence & confidence

This is a Form 4 insider sale with no 10b5-1 plan stated and no accompanying company-specific operational/regulatory catalyst in the text.

Market effects

Sector

None indicated; single insider sale does not reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be non-informational (taxes, diversification, planned liquidity), especially when not tied to a company event.

Key entities

  • issuer
    Ligand Pharmaceuticals Inc

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Sabba Stephen L

    Director who sold 2,145 shares at $254/share on 2026-06-16.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LGND insider trading history →

Related articles

SEP 27
$LGNDMed

Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones

Ligand Pharmaceuticals (LGND) announced a $47M financing deal with AvenCell Therapeutics, including $6M for Series C funding and $41M for drug development, tied to milestones. Ligand aims for mid-single-digit to low-double-digit royalties on AvenCell's sales. The company's royalty revenue grew 32% YoY to $48M in Q2, with a target of $225M-$250M for 2026. Ligand has $1.36B in cash and $700M for further investments.

insidermonkey.com2 min
SEP 24
$LGNDMed

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million JUPITER, Fla., September 24, 2026 – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a f

SEC EDGAR 8-K1 min
SEP 4
$LGNDHighAI 8/10

Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book

Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 32% YoY, driven by royalty revenue growth. The company acquired XOMA Royalty, doubling its royalty portfolio and adding $700M in convertible debt. Ligand raised its full-year adjusted earnings guidance, but expenses increased due to the acquisition and other costs. The stock trades at a forward P/E of 25.19.

insidermonkey.com3 min
AUG 13
$LGNDHighAI 9/10

Ligand (LGND) Q2 2026 Earnings Call Transcript

Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 34%, driven by $48.0M royalty revenue (+32%). Adjusted diluted EPS was $2.37 (+48%). 2026 guidance raised to adjusted EPS $9.00-$9.50 and revenue $270M-$310M. Cash and short-term investments were $1.36B after a $700M convertible note. The XOMA Royalty acquisition added 120 assets.

fool.com6 min
AUG 8
$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

yahoo.com7 min